SV Life Sciences (SVLS) has appointed Dr. Heiner Dreismann as venture partner. Dr. Dreismann joins SVLS with more than 26 years of experience in the health care industry.
SV Life Sciences (“SVLS”) today announced the appointment of Dr. Heiner Dreismann, as Venture Partner. Dr. Dreismann joins SVLS with more than 26 years of experience in the health care industry.
“We are very excited to welcome Dr. Dreismann to SVLS,” said Lutz Giebel, SVLS Managing Partner. “Dr. Dreismann will join our biotechnology team and focus on investments in the diagnostics space. We believe favorable market dynamics make this a perfect time to expand our capabilities in this area and Dr. Dreismann’s knowledge and expertise will be invaluable assets as we do so.”
Dr. Dreismann is highly regarded in the healthcare industry with over 26 years of experience. He serves on the boards of several innovative public and private diagnostic companies. Dreismann completed a successful career at Roche Group from 1985 to 2006 where he held several senior positions including President and CEO of Roche Molecular Systems, Head of Global Business Development at Roche Diagnostics and Member of Roche’s Global Diagnostic Executive Committee.
“Joining SVLS is a tremendous opportunity for me to bring my expertise in diagnostics and life sciences to venture capital investing,” said Dreismann. “SVLS has a stellar market reputation and I look forward to helping grow the diagnostics vertical in the firm’s portfolio.”
Dr. Dreismann earned a Master of Science in biology and a Doctor of Philosophy in microbiology/molecular biology from Westfaelische Wilhelms University in Muenster, Germany. He conducted his Post-Doctoral studies in microbial genetics at the Centre d’Etudes Nucleaires de Saclay, France. Dr. Dreismann is an active member of the in vitro diagnostics (IVD) industry community and is regarded as a pioneer in the early adoption of the polymerase chain reaction (PCR) technique.
Dr. Dreismann is a member of SVLS’ team of 35 professionals organized according to experience and specialization into three practice areas: Biotechnology / Biopharmaceuticals; Medical Devices / Instrumentation; and Healthcare Services. These individuals’ diverse and complimentary skill sets and experiences enable SVLS to tailor an investment team for almost any life science business. Typically, SVLS recruits operating executives, called Venture Partners, who have distinguished careers in the life sciences fields and can bring extensive operating expertise to the SVLS portfolio of investments. They assist in sourcing, building and exiting investments successfully. SVLS employs a close symbiosis between operating and financial professionals which has led to significant success over five investment funds.
About SV Life Sciences
SV Life Sciences is a leading international life sciences venture capital firm. SVLS affiliated funds have been investing in life sciences companies since the early 1980s and the firm closed its first dedicated life sciences fund in 1994. The SVLS team manages five venture capital funds with approximately $2 billion of capital under management. The Firm employs a diversified strategy within life sciences in order to selectively capitalize on an expanding opportunity in biotech, medical devices and health-care services. SVLS has offices in Boston, London and San Francisco. For more information, please visit the company’s website at http://www.svlsa.com.
Partner and CFO
SV Life Sciences
T: +1 617 367 8100
Email : firstname.lastname@example.org
Lutz Giebel, PhD
SV Life Sciences
T: +1 650 571 8200
T: +1 212 232 2222